Phase-1 Molecular Toxicology Inc. has announced a large collaborative research agreement with Boehringer Ingelheim Pharmaceuticals Inc. to develop diagnostic technologies to identify which patients will suffer from adverse reactions to drugs prior to treatment.
Spencer Farr, Ph.D. CEO of Phase-1 had this to say about the collaboration with Boehringer Ingelheim Pharmaceuticals: “We believe that this agreement with Boehringer Ingelheim Pharmaceuticals takes us much closer to being able to identify patients at risk of adverse responses.
Boehringer Ingelheim Pharmaceuticals has been a leader in developing and championing cutting edge approaches to predicting drug toxicity and we are pleased they wish to continue in that leadership position in close collaboration with Phase-1.”Dr. Ray Stoll, director of Drug Safety at Boehringer Ingelheim Pharmaceuticals Inc. said, “Boehringer Ingelheim Pharmaceuticals have ongoing collaborative research agreements with Phase-1 Molecular Toxicology.
For the past three years, as well as for the foreseeable future, our collaborations have been productive and allowed us to use new genomic research tools in the mechanistic and regulatory toxicology field in our pursuit of new drug entities.”Phase-1 Molecular Toxicology Inc. is the pioneer molecular toxicology company.
Phase-1’s products and services use gene expression technologies, proteomics, and bio-informatics to improve lead optimisation, to expand the understanding of fundamental mechanisms of toxicity, and to increase the throughput rate of toxicological screening.